osimertinib - For the treatment of locally advanced (not amenable to curative therapies) or metastatic non-small cell lung cancer (NSCLC), based on criteria
Exceptional Access Program
osimertinib - For the treatment of locally advanced, unresectable (stage III) non-squamous non-small cell lung cancer (NSCLC), based on criteria
ripretinib - For adult patients with advanced gastrointestinal stromal tumours (GIST) who have progression on or intolerance to imatinib, sunitinib and regorafenib